🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 41 of 116

  1. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  4. Cemiplimab

    Regeneron UK Limited

    Colon and Rectal Cancer

    phase 2 small molecule active

    1 trial

  5. Cemiplimab

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  6. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  7. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  8. Cemiplimab

    Regeneron UK Limited

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  9. Cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  12. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  13. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  15. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  16. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  17. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  19. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  20. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  21. Ceralasertib

    United Therapeutics Europe Ltd

    Gynaecological Cancers

    phase 2 small molecule active

    1 trial

  22. Ceritinib (LDK378)

    Novartis Pharmaceuticals

    Tumors With Aberrations in ALK

    phase 2 small molecule terminated

    1 trial

  23. Cetrelimab

    Janssen Cilag International NV

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  24. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  25. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  26. Cetuximab

    Solid Biosciences

    Head and Neck Neoplasm

    phase 2 small molecule completed

    1 trial

  27. Cetuximab β；Fruquintinib；

    Zhejiang University

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  28. Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin

    Hospital Authority, Hong Kong

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  29. ChAdOx1-MVA 5T4 vaccine

    Barinthus Biotherapeutics plc.

    Intermediate Risk Prostate Cancer

    phase 2 mab terminated

    1 trial

  30. ChAdOx1-PCAQ

    Barinthus Biotherapeutics plc.

    Prostate Cancer

    phase 2 mab terminated

    1 trial

  31. Chemotherapy + immunotherapy

    Hunan Province Tumor Hospital

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. Chemotherapy plus apatinib

    Lei Li

    Recurrent Cervical Carcinoma

    phase 2 small molecule completed

    1 trial

  33. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  34. Chidamide

    Sun Yat-sen University

    Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  35. Chidamide

    Biotech Pharmaceutical Co.,

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule terminated

    1 trial

  36. Chidamide

    Biotech Pharmaceutical Co.,

    Relapsed or Refractory Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  37. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  38. Chidamide + Tislelizumab + chemotherapy (CapeOX )

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  39. Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  40. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  41. Chinese Medicine Oral Rinse Formula-I (CMORF-I)

    Chinese University of Hong Kong

    Head and Neck Neoplasms

    phase 2 small molecule active

    1 trial

  42. Chlorambucil

    Teva Pharma GmbH

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  43. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  44. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  45. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  46. Cisplatin

    Ultragenyx UK Limited

    Squamous Cell Carcinoma of the Anus

    phase 2 small molecule active

    1 trial

  47. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord Healthcare 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Vulvar cancer

    phase 2 small molecule active

    1 trial

  48. Cisplatin and Doxorubicin

    Chinese University of Hong Kong

    Gastric Cancer Peritoneal Metastases

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.